Literature DB >> 10454490

Discriminative stimulus effects of the nonpeptidic delta-opioid agonist SNC80 in rhesus monkeys.

M R Brandt1, S S Negus, N K Mello, M S Furness, X Zhang, K C Rice.   

Abstract

Five rhesus monkeys were trained to discriminate the nonpeptidic, delta-opioid agonist SNC80 (0.32 mg/kg i.m.) from saline by using a food-reinforced drug-discrimination procedure. Cumulative doses of SNC80 produced a dose-dependent increase in SNC80-appropriate responding and a dose-dependent decrease in response rate. In time-course studies, peak effects of the training dose of SNC80 were observed after 15 min, and these effects diminished over 240 min. In substitution studies, other piperazinyl benzamide delta agonists (SNC86, SNC162, and SNC243A) substituted for SNC80 with relative potencies similar those of SNC80. However, SNC67, the (-)-enantiomer of SNC80, did not occasion SNC80-appropriate responding up to a dose (32.0 mg/kg) that produced convulsions in one monkey. The mu agonists morphine and fentanyl and the kappa agonists U-50,488 and enadoline failed to substitute for SNC80 up to doses that eliminated responding. Two nonopioids (the N-methyl-D-aspartate antagonist ketamine and the monoamine reuptake inhibitor cocaine) also produced primarily saline-appropriate responding. Both the discriminative stimulus and rate-decreasing effects of SNC80 were antagonized by the delta-selective antagonist naltrindole (0.01-1.0 mg/kg) but not by doses of the opioid antagonist quadazocine (0.1-1.0 mg/kg) that block the effects of mu and kappa agonists. These data suggest that the discriminative stimulus effects of SNC80 are mediated by delta-opioid receptors and that the discriminative stimulus effects of delta opioids in primates can be differentiated from the effects of other opioid and nonopioid compounds.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454490

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys.

Authors:  Ingela Danielsson; Maciej Gasior; Glenn W Stevenson; John E Folk; Kenner C Rice; S Stevens Negus
Journal:  Pharmacol Biochem Behav       Date:  2006-11-15       Impact factor: 3.533

2.  Effects of the selective delta opioid agonist SNC80 on cocaine- and food-maintained responding in rhesus monkeys.

Authors:  Gail Pereira Do Carmo; Nancy K Mello; Kenner C Rice; John E Folk; S Stevens Negus
Journal:  Eur J Pharmacol       Date:  2006-07-05       Impact factor: 4.432

3.  Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeys.

Authors:  Ajay S Yekkirala; Matthew L Banks; Mary M Lunzer; Stevens S Negus; Kenner C Rice; Philip S Portoghese
Journal:  ACS Chem Neurosci       Date:  2012-07-05       Impact factor: 4.418

4.  The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects.

Authors:  Eduardo R Butelman; Szymon Rus; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2010-01-19       Impact factor: 4.530

5.  Asymmetric generalization and interaction profiles in rhesus monkeys discriminating intravenous cocaine or intravenous heroin from vehicle.

Authors:  Donna M Platt; James K Rowlett; Roger D Spealman
Journal:  J Pharmacol Exp Ther       Date:  2009-12-04       Impact factor: 4.030

6.  The selective non-peptidic delta opioid agonist SNC80 does not facilitate intracranial self-stimulation in rats.

Authors:  Gail Pereira Do Carmo; John E Folk; Kenner C Rice; Elena Chartoff; William A Carlezon; S Stevens Negus
Journal:  Eur J Pharmacol       Date:  2008-12-24       Impact factor: 4.432

7.  Characterization of the Discriminative Stimulus Effects of a NOP Receptor Agonist Ro 64-6198 in Rhesus Monkeys.

Authors:  Phillip A Saccone; Kathy A Zelenock; Angela M Lindsey; Agnieszka Sulima; Kenner C Rice; Eric P Prinssen; Jürgen Wichmann; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2016-01-22       Impact factor: 4.030

8.  Synergistic activity between the delta-opioid agonist SNC80 and amphetamine occurs via a glutamatergic NMDA-receptor dependent mechanism.

Authors:  Kelly E Bosse; Emily M Jutkiewicz; Kristin N Schultz-Kuszak; Omar S Mabrouk; Robert T Kennedy; Margaret E Gnegy; John R Traynor
Journal:  Neuropharmacology       Date:  2013-09-10       Impact factor: 5.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.